Navigation Links
Avidity Biosciences Announces Publication on Targeting Therapeutic Oligonucleotides by Arthur A. Levin in the New England Journal of Medicine
Date:1/5/2017

LA JOLLA, Calif., Jan. 4, 2017 /PRNewswire/ -- Avidity Biosciences LLC, a biotechnology company advancing Antibody-siRNA Conjugates (ASCs) as a new class of precision medicines, today announced a publication entitled, "Targeting Therapeutic Oligonucleotides," in the January 5, 2017 issue of the New England Journal of Medicine.1 The publication, authored by Arthur A. Levin, Ph.D., executive vice president of research and development, appears in the Clinical Implications of Basic Research section.

In the publication, Dr. Levin summarizes the advantages of targeted strategies for the delivery of therapeutic oligonucleotides. 

"Recent work indicates that the usefulness of therapeutic oligonucleotides can be increased by conjugating oligonucleotides with targeting moieties so that they home to specific cell types," said Dr. Levin. "Targeted delivery was determined to result in a median effective dose that was one thirtieth of that associated with non-targeted delivery, which clearly underscored the potential advantage of the approach."

Levin continues, "There remains a need to target non-hepatic cells specifically and efficiently: a means to achieve this goal could lie in the exploitation of the natural heterogeneity of cell surface receptors."

Dr. Levin has an unparalleled track record and reputation in the field of nucleic acid-based therapeutics. Prior to his role at Avidity Biosciences, he held senior drug development roles at miRagen Therapeutics, Ionis Pharmaceuticals and Santaris Pharma. He has played key roles in the development of numerous oligonucleotides, including the first approved antisense NDAs and the first microRNA-targeted therapeutic in clinical trials. He has a combined three decades of experience in all aspects of drug development from discovery through drug registration, both in large pharma and biotech companies. Dr. Levin has published over 60 scientific articles and has several of the most cited reviews in the field. He serves as a director of the Oligonucleotide Therapeutics Society and holds several additional scientific organization affiliations and honors. He received a doctorate in toxicology from the University of Rochester and a bachelor's degree in biology from Muhlenberg College.

About Avidity Biosciences

Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASCs) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics. Avidity is collaborating with partners to discover and develop best-in-class drug candidates against important undrugged therapeutic targets. The company has entered research collaborations with leading biopharma companies and is actively seeking additional partnerships. Avidity has raised $25 million in venture financing from a top-tier group of sophisticated healthcare investors.  More information about Avidity Biosciences can be found on the company's website at www.aviditybiosciences.com.

1  Levin, A, Targeting therapeutic oligonucleotides. N Engl J Med 2016;376: 86-88.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avidity-biosciences-announces-publication-on-targeting-therapeutic-oligonucleotides-by-arthur-a-levin-in-the-new-england-journal-of-medicine-300385825.html


'/>"/>
SOURCE Avidity Biosciences
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Biotech Stocks on Investors Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx
2. Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down
3. DuPont Industrial Biosciences to Begin New Research Aimed to Enable Global Access for Protein Medications
4. Roche announces termination of 2013 Development, Commercialization and License Agreement with Pacific Biosciences
5. ACEA Biosciences Presents Efficacy and Safety Data From AC0010 Phase I/II Clinical Trial for Treatment of Advanced Non-Small Cell Lung Cancer at the WCLC 2016 Conference
6. ACEA Biosciences Announces Data Presentation at WCLC 2016 Conference: New AC0010 Data to Be Presented
7. Vigene Biosciences Acquires the cGMP Manufacturing Facility and Assets of Omnia Biosciences
8. ACEA Biosciences Appoints Li Xu, M.D. as Chief Medical Officer
9. DuPont Industrial Biosciences and MIAVIT Announce Supply Agreement for Biogas Enzymes
10. Agro BioSciences Expands Probiotic Strain Portfolio
11. ARMO BioSciences Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the U.S. FDA for the Treatment of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2020)... WESTBURY, N.Y. (PRWEB) , ... May 14, 2020 , ... ... to get unforeseen and the most pressing questions answered quickly as the need arises. ... compliance-related topics, offering valuable advice at affordable rates. , Lachman OnCall™ SMEs are ...
(Date:5/14/2020)... ... May 12, 2020 , ... DuPont ... new distribution partner for all personal care ingredients in Russia and Belarus. Beginning ... DuPont preservative portfolio for personal care. , The GENENCARE®OSMS product line ...
(Date:5/14/2020)... ... May 13, 2020 , ... In collaboration with Sartorius, ... in the Life Science Lab . The comprehensive information source was created for ... and liquid handling to contamination control. , The content hub features the latest ...
(Date:5/9/2020)... (PRWEB) , ... May 08, 2020 , ... Worldwide ... of their successful business program on Sunday, May 10, 2020 and Wednesday, May 13, ... coast! This episode’s exclusive interviews will spotlight key executives from Techolution and ...
Breaking Biology Technology:
(Date:5/1/2020)... ... April 30, 2020 , ... ... by Siemens Healthineers and several healthcare VC firms announces an official launch of ... CareDoctors.com is to enhance patient care experience by offering live video consultations with ...
(Date:5/1/2020)... ... April 30, 2020 , ... InBios International Inc., a leading ... been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), ... the U.S. Department of Health and Human Services, to develop the SCoV-2 Detect ...
(Date:4/30/2020)... LOS ALAMOS, N.M. (PRWEB) , ... April 28, 2020 , ... ... some of the world’s biggest challenges in agriculture and aquaculture with the mission of ... eight presenters at the 2020 F&A Next ' Next Heroes in Food- and Ag-Tech ...
Breaking Biology News(10 mins):